Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

High throughput HLA sequence-based typing (SBT) utilizing the ABI Prism 3700 DNA Analyzer.

Adams SD, Barracchini KC, Simonis TB, Stroncek D, Marincola FM.

Tumori. 2001 Mar-Apr;87(2):S40-3.

PMID:
11401225
2.

Generation of alloantigen-stimulated anti-human immunodeficiency virus activity is associated with HLA-A*02 expression.

Grene E, Pinto LA, Cohen SS, Mac Trubey C, Trivett MT, Simonis TB, Liewehr DJ, Steinberg SM, Shearer GM.

J Infect Dis. 2001 Feb 1;183(3):409-16. Epub 2000 Dec 27.

PMID:
11133372
3.

Frequency of human leukocyte antigen-A 24 alleles in patients with melanoma determined by human leukocyte antigen-A sequence-based typing.

Bettinotti MP, Norris RD, Hackett JA, Thompson CO, Simonis TB, Stroncek D, Marincola FM.

J Immunother. 2000 Mar-Apr;23(2):282-7.

PMID:
10746555
4.

High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis.

Kicklighter EJ, Lee KH, Barracchini KC, Bettinotti M, Norris R, Simonis TB, Stroncek D, Marincola FM.

J Immunother. 1999 May;22(3):219-28.

PMID:
10335481
5.

Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.

Player MA, Barracchini KC, Simonis TB, Rivoltini L, Arienti F, Castelli C, Mazzocchi A, Belli F, Parmiani G, Marincola FM.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):357-63.

PMID:
8941875
6.

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.

Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):192-205.

PMID:
8811494
7.

Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma.

Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA.

Hepatology. 1996 May;23(5):1181-8.

PMID:
8621152
8.

Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma.

Kim CJ, Taubenberger JK, Simonis TB, White DE, Rosenberg SA, Marincola FM.

J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):50-8.

PMID:
8859724
9.

HLA associations in the antitumor response against malignant melanoma.

Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR.

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):242-52.

10.

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, et al.

Cancer Res. 1995 Jul 15;55(14):3149-57.

11.

Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.

Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, et al.

J Immunol. 1994 Aug 1;153(3):1225-37.

PMID:
8027550
12.

Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O'Dea T, Fetsch P, Yannelli J, Restifo NP, Mulé JJ, et al.

J Immunother Emphasis Tumor Immunol. 1994 Jul;16(1):13-23.

13.

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.

Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR.

Cancer Res. 1992 Dec 1;52(23):6561-6. Erratum in: Cancer Res 1993 Aug 15;53(16):3846. Cancer Res 1993 Dec 15;53(24):6079.

14.

Bulk cryopreservation of lymphocytes in glycerol.

Areman EM, Simonis TB, Carter CS, Read EJ, Klein HG.

Transfusion. 1988 Mar-Apr;28(2):151-6.

PMID:
2965440

Supplemental Content

Loading ...
Support Center